Search Results
Aug 26, 2026, 07:00 ET Vivace Therapeutics Strengthens Leadership Team as It Prepares to Advance VT3989, the First TEAD Inhibitor to enter Phase 3 Clinical Trials, as the Leading Treatment for Mesothelioma
transcription by YAP/TAZ/TEAD which is activated in mesothelioma tumor cells, has generated impressive overall response (ORR) and progression-free survival (PFS) and tolerability data in patients with refractory mesothelioma as a monotherapy. In addition to the safe to proceed for the Phase 3 sTEADfast clinical
More news about: Vivace Therapeutics, Inc.
Aug 25, 2026, 17:00 ET Ivonescimab Plus Chemotherapy Demonstrates Significant Overall Survival Benefit Versus Durvalumab Plus Chemotherapy in First-Line Biliary Tract Cancer: HARMONi-GI1 Meets Primary Endpoint
a clinically meaningful and statistically significant positive result. The study also met all key secondary endpoints of progression-free survival (PFS) and objective response rate (ORR). Detailed results from this study will be presented at an upcoming international academic conference and published
More news about: Akeso, Inc.
Aug 25, 2026, 10:00 ET U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma
Results Progression-free survival (PFS): Both Ziihera-containing combinations significantly improved PFS in the overall HER2+ population, reducing the risk of disease progression or death by 35% and extending median PFS to 12.4 months versus 8.1 months with trastuzumab plus
More news about: Jazz Pharmaceuticals plc
Aug 24, 2026, 12:38 ET Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action Lawsuit - Hagens Berman Sobol Shapiro LLP
Study's primary endpoint was progression-free survival ("PFS") and Regeneron has characterized the combination as a "potential blockbuster." "Events" – disease progression or death – determined the timing and statistical power of the primary PFS analysis.The complaint alleges that
More news about: Hagens Berman Sobol Shapiro LLP
Aug 24, 2026, 07:00 ET MAYFAIR GOLD APPOINTS CHIEF PROJECTS OFFICER AND SENIOR VICE PRESIDENT, SUSTAINABILITY AS FENN-GIB ADVANCES TOWARD DEVELOPMENT
(the "PFS")1 is to develop the project under the provincial permitting process, targeting the higher-grade 1 million ounce probable mineral reserve (25.1Mt at an average grade of 1.29g/t) sitting near-surface, highlighting the optionality and scalability provided by the deposit. The PFS also
More news about: Mayfair Gold Corp.
Aug 24, 2026, 07:00 ET Hot Chili Delivers More Copper-Gold at La Verde
single-shift).As Hot Chili advances toward a maiden MRE for La Verde later this year, the Company expects to follow with a revised Pre-Feasibility Study (PFS) for Costa Fuego, including La Verde, and the formal submission of the Costa Fuego Environmental Impact Assessment (EIA) in Q2 2027.The integration
More news about: Hot Chili Limited
Aug 23, 2026, 20:00 ET Anbogen Therapeutics and The University of Tokyo Enter Collaborative Research Agreement to Evaluate ABT-301 Across Multiple Tumor Types, Targeting Accelerated Human Clinical Indication Expansion
checkpoint inhibitors have demonstrated significant synergistic efficacy in advanced cancers, including a marked improvement in progression-free survival (PFS). These external clinical findings provide strong proof-of-concept for the HDAC inhibitor–immune checkpoint inhibitor combination strategy and further
More news about: AnBogen Therapeutics
Aug 23, 2026, 20:00 ET Anbogen Therapeutics and The University of Tokyo Enter Collaborative Research Agreement to Evaluate ABT-301 Across Multiple Tumor Types, Targeting Accelerated Human Clinical Indication Expansion
checkpoint inhibitors have demonstrated significant synergistic efficacy in advanced cancers, including a marked improvement in progression-free survival (PFS). These external clinical findings provide strong proof-of-concept for the HDAC inhibitor–immune checkpoint inhibitor combination strategy and further
More news about: AnBogen Therapeutics
Aug 20, 2026, 13:05 ET REGN Shareholder Alert: September 14, 2026 Lead Plaintiff Deadline in Regeneron Pharmaceuticals Securities Class Action - Contact SueWallSt
expanding the PFS cohort suggested that the underlying benefit may be insufficient to show statistical significance.Analyst Coverage TimelineWells Fargo attributed REGN's April 29 share decline primarily to the Company's decision to expand the PFS cohort.The
More news about: SueWallSt.com
Aug 20, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGN
the "Phase 3 Trial of Fianlimab . . . did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS)." On this news, Regeneron's stock price fell $68.57 per share, or 9.82%, to close at $629.68 per share on May 16, 2026.Pomerantz LLP, with
More news about: Pomerantz LLP
Aug 20, 2026, 09:28 ET Regeneron Pharmaceuticals, Inc. (REGN) Investors: September 14, 2026 Lead Plaintiff Deadline in Class Action Lawsuit
Study's primary endpoint was progression-free survival ("PFS") and Regeneron has characterized the combination as a "potential blockbuster." "Events" – disease progression or death – determined the timing and statistical power of the primary PFS analysis.The complaint alleges that
More news about: Hagens Berman Sobol Shapiro LLP
Aug 20, 2026, 08:00 ET Nuvation Bio Granted FDA Fast Track Designation for Safusidenib for Treatment of IDH1-Mutant Glioma
study, treatment with safusidenib showed a confirmed objective response rate (cORR) of 51.9%, with median progression-free survival (PFS) not yet reached and a 36-month PFS rate of 79.1%, and only one patient who had previously responded experienced subsequent disease progression. No new safety signals
More news about: Nuvation Bio Inc.
Aug 19, 2026, 22:26 ET REGN Stockholders Interested in Leading the Class Action Against Regeneron Pharmaceuticals, Inc. Should Contact Robbins LLP for Information About Recovering Their Losses
disclosed that the Phase 3 Fianlimab-Libtayo study had been modified to expand the number of patients eligible for analysis of progression-free survival (PFS).Following the disclosure, Regeneron's stock price fell from $731.77 per share on April 28, 2026, to $686.36 per share on April 29, 2026, a decline
More news about: Robbins LLP
Aug 19, 2026, 13:12 ET REGN Investor Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action Notice - Contact Levi & Korsinsky
altered to expand the patient population eligible for PFS analysis.A second market reaction followed Regeneron's May 15, 2026 announcement that the Phase 3 trial did not reach statistical significance for the primary endpoint of improvement in PFS. The lawsuit asserts that these disclosures corrected
More news about: Levi & Korsinsky, LLP
Aug 19, 2026, 11:30 ET Pets are Family, and Budgets Show It: New AICPA Survey Finds Owners Prioritize Pet Care and Long-Term Planning
getting their pet(s)."Many people overlook what would happen to their pet(s) if they became incapacitated or pass away," said Erin Itkoe, CPA/PFS, member of AICPA's PFP Champions Task Force. "Discussing long-term care arrangements for your pet(s) and documenting those wishes in your estate plan
More news about: AICPA
Aug 18, 2026, 10:11 ET REGN Shareholder Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact The Gross Law Firm
the "Phase 3 Trial of Fianlimab . . . did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS)." Following this news, the price of Regeneron's common stock declined even further. From a closing market price of $698.25 per share on May 15, 2026,
More news about: The Gross Law Firm
Aug 18, 2026, 09:00 ET PM360 Announces 2026 Trailblazer Award Finalists
Squibb Speeds the Path to Compliant Content with Agentic MLR (Bristol Myers Squibb and Veeva)Predictev™ (Inizio Evoke)VYVGART Hytrulo PFS: Precision HCP Media at the point of Decision (argenx and Real Chemistry)CONSUMER WEBSITE/ONLINE INITIATIVEDETECT
More news about: PM360
Aug 18, 2026, 06:23 ET Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action Lawsuit - Hagens Berman Sobol Shapiro LLP
Study's primary endpoint was progression-free survival ("PFS") and Regeneron has characterized the combination as a "potential blockbuster." "Events" – disease progression or death – determined the timing and statistical power of the primary PFS analysis.The complaint
More news about: Hagens Berman Sobol Shapiro LLP
Aug 17, 2026, 07:18 ET Kelun-Biotech Announces 2026 Interim Results
published in The Lancet. Compared with single-agent immunotherapy, this combination regimen yielded a significant prolongation in PFS (HR = 0.35), with consistent PFS benefits observed across all predefined subgroups; an OS benefit trend was also observed (HR = 0.55).The final OS analysis
More news about: Kelun-biotech
Aug 16, 2026, 20:00 ET AbelZeta Regains Global Rights of C-CAR039 (Prizlon-cel) and Receives FDA Clearance of IND Application in Large B-cell Lymphoma
favorable safety profile and deep and durable responses, with an overall response rate (ORR) of 91.5% and complete response (CR) rate of 85.1%. Median PFS was 60.1 months at a median follow-up of 53.9 months."We are pleased to welcome C-CAR039 back to our hematology malignancy portfolio," said Tony
More news about: AbelZeta Pharma, Inc.
Aug 14, 2026, 15:34 ET Regeneron Pharmaceuticals, Inc. (REGN) Investors: September 14, 2026 Lead Plaintiff Deadline in Class Action Lawsuit - Hagens Berman
Study's primary endpoint was progression-free survival ("PFS") and Regeneron has characterized the combination as a "potential blockbuster." "Events" – disease progression or death – determined the timing and statistical power of the primary PFS analysis.The complaint alleges that
More news about: Hagens Berman Sobol Shapiro LLP
Aug 13, 2026, 16:04 ET Inhibrx Reports Second Quarter 2026 Financial Results
future increments of $50.0 million or more.INBRX-106The Company plans to announce progression-free survival (PFS) data from the randomized Phase 2 trial in head and neck squamous cell carcinoma (HNSCC) in combination with pembrolizumab in the third quarter of 2026.
More news about: Inhibrx Biosciences, Inc.
Aug 13, 2026, 12:50 ET REGN Shareholder Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action Lawsuit - Investors Should Contact SueWallSt
expanded patient population for PFS analysis and then failed to reach statistical significance on its primary endpoint.Timeline of Alleged Disclosure FailuresAugust 1, 2025: Regeneron stated that enrollment for the PFS cohort had completed, but results
More news about: SueWallSt.com
Aug 13, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGN
the "Phase 3 Trial of Fianlimab . . . did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS)." On this news, Regeneron's stock price fell $68.57 per share, or 9.82%, to close at $629.68 per share on May 16, 2026.Pomerantz LLP, with
More news about: Pomerantz LLP
Aug 13, 2026, 07:30 ET ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates
the LOTIS-5 Phase 3 confirmatory trial of ZYNLONTA in combination with rituximab, which met the trial's primary endpoint of progression-free survival (PFS). The Company submitted full data to ASH.The Company recently held a pre-sBLA meeting with the FDA. During this meeting, the FDA noted substantial
More news about: ADC Therapeutics SA